China Mycoplasma Testing Market Size & Outlook, 2025-2033

The mycoplasma testing market in China is expected to reach a projected revenue of US$ 142.9 million by 2033. A compound annual growth rate of 14.1% is expected of China mycoplasma testing market from 2025 to 2033.
Revenue, 2024 (US$M)
$44.1
Forecast, 2033 (US$M)
$142.9
CAGR, 2025 - 2033
14.1%
Report Coverage
China

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

China mycoplasma testing market, 2021-2033 (US$M)

To keep accessing Horizon, please sign in or register for a free account

  • Access to global market statistics
  • Access to company profiles
  • Free use-cases & research insights

No credit card required*

China mycoplasma testing market highlights

  • The China mycoplasma testing market generated a revenue of USD 44.1 million in 2024 and is expected to reach USD 142.9 million by 2033.
  • The China market is expected to grow at a CAGR of 14.1% from 2025 to 2033.
  • In terms of segment, kits & reagents was the largest revenue generating product in 2024.
  • Services is the most lucrative product segment registering the fastest growth during the forecast period.


Mycoplasma testing market data book summary

Market revenue in 2024USD 44.1 million
Market revenue in 2033USD 142.9 million
Growth rate14.1% (CAGR from 2025 to 2033)
Largest segmentKits & reagents
Fastest growing segmentServices
Historical data2021 - 2023
Base year2024
Forecast period2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationInstruments, Kits & Reagents, Services
Key market players worldwideThermo Fisher Scientific Inc, Lonza Group Ltd, Merck KGaA, Charles River Laboratories International Inc, Asahi Kasei Corp, Sartorius AG, Eurofins Scientific SE, PromoCell GmbH, ATCC, InvivoGen


Other key industry trends

  • In terms of revenue, China accounted for 4.3% of the global mycoplasma testing market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In Asia Pacific, Japan mycoplasma testing market is projected to lead the regional market in terms of revenue in 2033.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 119.9 million by 2033.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Mycoplasma Testing Market Companies

Name Profile # Employees HQ Website
InvivoGen View profile 101-250 Toulouse, Midi-Pyrenees, France, Europe http://invivogen.com
ATCC View profile 501-1000 Manassas, Virginia, United States, North America https://www.atcc.org/en.aspx
PromoCell GmbH View profile 51-100 Heidelberg, Baden-Wurttemberg, Germany, Europe http://www.promocell.com/
Asahi Kasei Corp View profile 48897 1-105 Kanda Jinbocho, Chiyoda-ku, Tokyo, Japan, 101-8101 http://www.asahi-kasei.co.jp
Charles River Laboratories International Inc View profile 21400 251 Ballardvale Street, Wilmington, MA, United States, 01887 https://www.criver.com
Eurofins Scientific SE View profile 61798 23 Val Fleuri, Luxembourg, Luxembourg, L-1526 https://www.eurofins.com
Sartorius AG View profile 14338 Otto-Brenner-Strasse 20, Gottingen, NI, Germany, 37079 https://www.sartorius.com
Thermo Fisher Scientific Inc View profile 122000 168 Third Avenue, Waltham, MA, United States, 02451 https://www.thermofisher.com
Lonza Group Ltd View profile 18000 Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 https://www.lonza.com
Merck KGaA View profile 62345 Frankfurter Strasse 250, Darmstadt, HE, Germany, 64293 https://www.emdgroup.com

China mycoplasma testing market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mycoplasma testing market will help companies and investors design strategic landscapes.


Kits & reagents was the largest segment with a revenue share of 63.27% in 2024. Horizon Databook has segmented the China mycoplasma testing market based on instruments, kits & reagents, services covering the revenue growth of each sub-segment from 2021 to 2033.


The mycoplasma testing market in China is saturated, despite the low cost of production drives global investments in the country for manufacturing. For instance, in December 2021, Fujifilm announced building a new center for bioprocessing media in China. This center was aiming to provide media for biotherapeutics development, advanced therapies, & vaccines. In addition, in October 2023, Eminence Biotechnology started a GMP-grade manufacturing facility of cell culture media in Suzhou.

Furthermore, in July 2024, Merck initiated a GMP-grade cell culture media manufacturing facility in China. With an investment of over USD 6 million, the facility was expected to support local biopharma manufacturing. Moreover, China is a pioneer in stem cell research, which is projected to drive the demand for mycoplasma testing.

The presence of global players, such as Thermo Fisher Scientific, Inc. & Merck KGaA, and local suppliers aids in meeting the diverse needs of R&D in the biopharmaceutical industry in the country.

Reasons to subscribe to China mycoplasma testing market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of China mycoplasma testing market databook

  • Our clientele includes a mix of mycoplasma testing market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the China mycoplasma testing market , including forecasts for subscribers. This country databook contains high-level insights into China mycoplasma testing market from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

China mycoplasma testing market size, by product, 2021-2033 (US$M)

China Mycoplasma Testing Market Outlook Share, 2024 & 2033 (US$M)

China mycoplasma testing market size, by product, 2021-2033 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more
Chat with us
Research Assistance
Online